Trial Profile
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Aug 2022
Price :
$35
*
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms TOWER
- Sponsors Sanofi
- 28 Jun 2022 Results of post-hoc analysis of two studies (TEMSO (NCT00134563) and TOWER (NCT00751881)) assessing effect of teriflunomide on various dGM structures, presented at the 8th Congress of the European Academy of Neurology.
- 26 May 2020 Results of pooled analysis from TEMSO, TOWER, TENERE, TOPIC and TERI-PRO assessing lymphocyte levels in teriflunomide-treated patients stratified by age, presented at the 6th Congress of the European Academy of Neurology
- 06 May 2019 According to a Sanofi Genzyme media release, post-hoc analysis of four clinical studies: a Phase 2 study, Phase III TEMSO, TOWER and TENERE core studies and their extensions, will be presented during the 71st annual meeting of the American Academy of Neurology (AAN) in Philadelphia, PA.